Medicine in Drug Discovery最新文献

{"title":"Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)","authors":"Daniela Bermeo Grajales ,&nbsp;Nermala Sewdat ,&nbsp;Ryan Leo ,&nbsp;Supratik Kar","doi":"10.1016/j.medidd.2023.100161","DOIUrl":"https://doi.org/10.1016/j.medidd.2023.100161","url":null,"abstract":"<div><p>Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abrocitinib emerged as a cutting-edge addition to its therapeutic category, gaining approval for utilization within the United States. Diverging from its predecessors in the realm of moderate to severe AD treatment, Abrocitinib distinguishes itself through its heightened specificity. Moreover, its tablet formulation facilitates straightforward administration, offering diverse dosage options. An additional noteworthy feature is its applicability to individuals aged 12 and above, making it an option for alleviating symptoms in this demographic. Within this comprehensive assessment, key aspects such as the biological target of the drug, developmental strategies, mode of operation, pharmacokinetics, pharmacodynamics, clinical trial insights, contraindications, potential interactions with other medications, and adverse reactions are examined. In light of the overarching perspective and available clinical evidence, Abrocitinib emerges as a promising orally bioavailable therapeutic, authorized for treating AD. Notably, it gained its initial approval in Japan for patients aged 12 years and older, marking a significant advancement in the realm of dermatological care.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"20 ","pages":"Article 100161"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50185701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics","authors":"Shama Parveen ,&nbsp;Pratishtha Gupta ,&nbsp;Saurabh Kumar ,&nbsp;Monisha Banerjee","doi":"10.1016/j.medidd.2023.100165","DOIUrl":"https://doi.org/10.1016/j.medidd.2023.100165","url":null,"abstract":"<div><p>Among all diseases, cancer has the highest fatality rate in the world. Conventional therapies have come a long way, but they still are not a panacea for cancer. Nanotechnology-based compositions of several nanoparticles (NPs) hold promise as a cancer therapy. The co-delivery of amphiphilic molecules is feasible with lipid-polymer hybrid nanoparticles (LPHNPs). Increased encapsulation of pharmaceuticals with a regulated release profile is made possible by the physical benefits of polymers and the resembling features of lipids. For increased cytotoxicity against cancer, LPHNPs have been created for the co-transport of phytochemicals and other chemotherapeutic medicines. Specifically, LPHNPs are used as carrier systems to deliver drugs to tumour locations in a regulated fashion. This method makes use of the biocompatibility of lipids and the structural advantages of polymers to provide controlled drug administration. Co-loaded LPHNPs demonstrated improved cytotoxicity, and the incorporation of phytochemicals into various medications resulted in enhanced chemo-sensitization of carcinomas. The shortcomings of existing nano-delivery systems and the benefits of LPHNPs have been discussed in this review.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"20 ","pages":"Article 100165"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590098623000155/pdfft?md5=802d0931ab91f1b914e07d7e152d9be6&pid=1-s2.0-S2590098623000155-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92016174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiopathic pulmonary fibrosis: Pathophysiology, cellular signaling, diagnostic and therapeutic approaches","authors":"Ilma Shakeel ,&nbsp;Mohammad Afzal ,&nbsp;Asimul Islam ,&nbsp;Sukhwinder Singh Sohal ,&nbsp;Md. Imtaiyaz Hassan","doi":"10.1016/j.medidd.2023.100167","DOIUrl":"https://doi.org/10.1016/j.medidd.2023.100167","url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF) is a life-threatening and progressive interstitial lung disease. Healthy pulmonary tissues were replaced by an altered extracellular matrix (ECM) and destroyed the alveolar architecture, which led to the disruption of gas exchange, decreased lung compliance, and ultimately led to the failure of respiration and death. IPF is associated with dyspnoea and cough, eventually impairing the quality of a large population worldwide, with the incidence rate increasing drastically with age. The IPF involves a complex pathophysiology; thus, it is necessary to understand the precise molecular mechanism for lung fibrosis to develop novel therapeutic options. Different kinases, including p38 mitogen-activated protein kinase, JNK (c-Jun N-terminal kinase), and SAPKs (Stress-activated protein kinases), were ubiquitously expressed in numerous variety of cells and were activated in response to inflammatory stimuli, cellular environmental stress, and stimuli for apoptosis. After many failed drugs for IPF in clinical trials, two drugs, namely nintedanib and pirfenidone, were approved, which helped to slow the disease progression. However, the prognosis of IPF remains poor, which leads to continuing the search for better drugs, targeting to either reduce or halt the disease progression. The current review summarises the pathophysiology, signaling, and role of different kinases, therapeutic interventions, investigational therapies, and biomarkers for IPF. A better understanding of the pathophysiology of IPF will be helpful to understand disease mechanisms, discovering potential biomarkers, and development of effective therapeutics to handle patients.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"20 ","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590098623000179/pdfft?md5=f6ca2bd731e41e6bac6b86302eabc7c9&pid=1-s2.0-S2590098623000179-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134657002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antisense oligonucleotide based therapeutics and its applications against bacterial infections","authors":"Nupur Angrish,&nbsp;Garima Khare","doi":"10.1016/j.medidd.2023.100166","DOIUrl":"https://doi.org/10.1016/j.medidd.2023.100166","url":null,"abstract":"<div><p>The transcriptome of a cell governs the overall cellular expression of proteins, hence, targeting mRNA holds promise as a therapeutic strategy in the field of drug discovery. RNA therapeutics especially, antisense oligonucleotide (ASO) technology, have gained tremendous pace in the last few decades with many of the ASOs being evaluated in various clinical phases and several ASO-based drugs are currently marketed after FDA approval. Several chemical modifications in the nucleic acid backbone of ASOs have led to improved properties of ASOs, such as oligonucleotide stability, enhanced affinity, and better pharmacokinetics contributing to their therapeutic success. ASOs interfere with the translation process either by RNase H-mediated mRNA cleavage or by posing steric hindrance in the translation machinery. Further, the cellular delivery of ASOs has always remained questionable, however, with the advancements in the delivery approaches, it is now feasible to achieve better target specific cellular delivery. In this review, we provide comprehensive insights into antisense oligonucleotide therapeutics, their various modifications, the mechanisms involved, different strategies for their delivery, and the utility of ASOs against several bacterial diseases.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"20 ","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590098623000167/pdfft?md5=acfe4b878a5a97af33599947d87be286&pid=1-s2.0-S2590098623000167-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134657003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An association between calcium channel blocker and breast cancer in patients with hypertension: A case-control study","authors":"Ratchata Supannaroj,&nbsp;Sittichai Khamsai,&nbsp;Jarin Chindaprasirt,&nbsp;Wattana Sukeepaisarnjaroen,&nbsp;Panita Limpawattana,&nbsp;Kittisak Sawanyawisuth","doi":"10.1016/j.medidd.2023.100168","DOIUrl":"https://doi.org/10.1016/j.medidd.2023.100168","url":null,"abstract":"<div><p>Hypertension is a common disease in clinical practice. Calcium channel blocker (CCB) is an effective antihypertensive agent. There is inconsistent data of an association of CCB and breast cancer in literatures particularly in breast cancer cytology. This study aimed to evaluate this association by a case-control design. The inclusion criteria were adult patients with an age of 18 years or over, diagnosed as hypertension, with a result of mammogram. Those who were pregnant, had no pathological results, or had breast mass prior to diagnosis of hypertension were excluded. Cases defined if the pathological report of any types of breast cancer, while controls were those with benign breast mass. Factors associated with breast cancer were calculated by logistic regression analysis. There were 299 patients met the study criteria. Of those, 100 patients (33.4 %) were in the case group or breast cancer group. There were three factors independently associated with breast cancer. CCB treatment had adjusted odds ratio of 2.25 (95 % confidence interval of 1.36, 3.77), while age of 50 years old or over and hormonal therapy also independently associated with breast cancer with adjusted odds ratios of 3.41 and 2.91, respectively. The CCB group had significantly higher proportion of ductal breast cancer than those who did not take CCB (42.5 % vs 23.8 %, p &lt; 0.001). CCB treatment may be associated with breast cancer especially ductal carcinoma in this study population.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"20 ","pages":"Article 100168"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590098623000180/pdfft?md5=ad27f860fb4827baa75c459ebec30262&pid=1-s2.0-S2590098623000180-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92046168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The difluoroboranyl-norfloxacin complex “7a” induces an antimicrobial effect against K. pneumoniae strain in acute pneumonia murine model","authors":"L. Angel Veyna-Hurtado ,&nbsp;Hiram Hernández-López ,&nbsp;Fuensanta Reyes-Escobedo ,&nbsp;Mitzzy Medellín-Luna ,&nbsp;Salvador García-Cruz ,&nbsp;Lorena Troncoso-Vázquez ,&nbsp;Irma E. González-Curiel ,&nbsp;Marisol Galván-Valencia ,&nbsp;Julio E. Castañeda-Delgado ,&nbsp;Alberto Rafael Cervantes-Villagrana","doi":"10.1016/j.medidd.2023.100160","DOIUrl":"10.1016/j.medidd.2023.100160","url":null,"abstract":"<div><p>The discovery and implementation of antibiotics led to a better prognosis for infectious diseases. Fluoroquinolones are a family of antibiotics with a broad spectrum of action and antibacterial effectiveness. Because bacterial strains have increased their resistance to antibiotics, the World Health Organization has reported an urgent need to develop new active molecules. Our research group has therefore focused on deriving different compounds from fluoroquinolones. A fluoroquinolone derivatized in complex with boron, labeled 7a, was found to have good antibacterial potential. The objective of this research was to evaluate the <em>in vitro</em> and <em>in vivo</em> antimicrobial effect of the derivatized 7a on <em>K. pneumoniae</em> (clinical isolates) strains. The Kirby-Bauer inhibition technique generated average inhibition areas of 8.24 ± 1.239 cm². For the minimum inhibitory concentration and minimum bactericidal concentration, macrodilutions of 7a compound were performed, obtaining 1 μg/mL in both determinations. For the <em>in vivo</em> model, Balb/c mice were infected intratracheally with <em>K. pneumoniae</em>; the animals were treated daily with ciprofloxacin (80 mg/kg/day) or 7a (80 mg/kg/day). The animals were sacrificed on the seventh day post-infection and hematoxylin and eosin staining was done on the lungs to evaluate the percentage of pneumonia. It was found that 7a significantly reduced the generation of pneumonia (5.96% of pneumonic tissue was found) while the untreated infected group generated 71.70% of pneumonic lung tissue. Compound 7a is an antimicrobial agent capable of inhibiting <em>in vitro</em> development of a Gram-negative (<em>K. pneumoniae</em>) bacterial strain. In addition, 7a is effective in treating acute pneumonia induced by <em>K. pneumoniae</em> in a murine model.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"19 ","pages":"Article 100160"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42835329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of adamantane derivative on expression of biofilm-associated genes in methicillin-resistant Staphylococcus aureus","authors":"Nataliia Humeniuk ,&nbsp;Liubov Zelena ,&nbsp;Nina Vrynchanu ,&nbsp;Liudmyla Ishchenko ,&nbsp;Tetiana Bukhtiarova ,&nbsp;Yurii Korotkij ,&nbsp;Elena Vazhnichaya","doi":"10.1016/j.medidd.2023.100155","DOIUrl":"10.1016/j.medidd.2023.100155","url":null,"abstract":"<div><p>In the etiology of nosocomial infections, the leading role belongs to such microorganisms as <em>Staphylococcus aureus.</em> Insufficient effectiveness of antimicrobial chemotherapy and practical absence of drugs with an antibiofilm activity encourage the development of new remedies. The study presents results on antibiofilm activity of the adamantane derivative 1-[4-(1-adamantyl)phenoxy]-3-(<em>N</em>-benzyl,<em>N</em>-dimethylamino)-2-propanol chloride (KVM-97) against methicillin-resistant <em>S. aureus</em> (MRSA) and the effect of this agent on the expression genes that provide regulatory and biosynthetic functions of biofilms. The ability of adamantane derivative to affect <em>S. aureus</em> biofilms was tested by microtiter dish biofilm formation assay. The effect of KVM-97 on expression level of genes <em>icaA, icaD, icaR, agrA, sarA, clfB</em>, <em>fib</em>, <em>fnbB</em>, <em>ebpS,</em> and <em>eno</em> was detected by the real-time PCR. The KVM-97 inhibits the formation of <em>S. aureus</em> biofilms at 5.0 MIC by 95.1 % and at 0.5 MIC – by 22.4 %. Under the action of KVM-97, destruction of the mature biofilms was not detected. It inhibits expression of the <em>icaADBC</em> operon and <em>agrA</em> gene, as well as stimulates a transcriptional activity of the <em>icaR</em> regulator. Subinhibitory concentrations of the KVM-97 significantly inhibit the expression of <em>clfB</em>, <em>fib</em>, <em>fnbB</em>, <em>ebpS</em>, and <em>eno</em>, but does not change the <em>sarA</em> gene expression. Thus, 1-[4-(1-adamantyl)phenoxy]-3-(<em>N</em>-benzyl,<em>N</em>-dimethylamino)-2-propanol chloride shows pronounced antibiofilm activity against MRSA at the early stages of the biofilm forming. This effect may be relating to influence on the expression of genes that regulate adhesion to the substrate and formation of <em>S. aureus</em> biofilms.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"18 ","pages":"Article 100155"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42578572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies","authors":"Shivam Rajput,&nbsp;Pramod Kumar Sharma,&nbsp;Rishabha Malviya","doi":"10.1016/j.medidd.2023.100158","DOIUrl":"10.1016/j.medidd.2023.100158","url":null,"abstract":"<div><p>Cancer patients have a shorter life expectancy because of metastasis, which is the dynamic chain of events that leads to the spread of tumour cells to distant places inside the body. Cancer's development, spread, metastasis, and treatment all involve fluid mechanics in some way. Cancer cells and their associated components take advantage of the body's many fluid systems as a means of dissemination throughout the body and colonisation of distant organs. Cancerous tissues rely on the blood supply for oxygen and nutrition, metastasis to other organs, and medication delivery. Cancer cells' ability to travel from the main tumour, extravasate, and seed metastases can be enhanced by exploiting the flow mechanics of the blood and lymphatic circulatory systems. Cancer cell survival in the circulation and the regulation of organotropic seeding patterns are affected by flow rates, channel size, and shear stress. Therefore, cancer cells not only use these fluids as a mode of transport throughout the body, but also as a fertile ground to seed distant metastases by taking advantage of the fundamental physical forces among these fluids. Metastasis, tumor growth, &amp; nanoparticle-mediated medication delivery is all under the control of multiscale flow-structure interaction processes, whereas an increase in interstitial pressure is caused by the tumour vasculature's irregularity and leakiness. This Review discusses the role that fluids play in metastasis, including the forces and stresses that are utilised by circulating tumour cells &amp; tumour-associated factors. Given the intriguing concerns raised by the role of physiological fluids and their mechanics in the biology of the metastatic cascade, gaining insight into this process may reveal a novel strategy for intercepting cancer cells on their route.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"18 ","pages":"Article 100158"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49192424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modality diversification and best-in-class small-molecule drugs: Recent trend of orphan drug development","authors":"Ryo Okuyama","doi":"10.1016/j.medidd.2023.100156","DOIUrl":"10.1016/j.medidd.2023.100156","url":null,"abstract":"<div><p>Only 5% of orphan diseases have approved drugs, leading to a high demand for new treatment. As a result, pharmaceutical companies have shifted their focus of drug development to orphan diseases. This study conducted a database search to analyze the modality and development strategy of orphan drugs approved by the Food and Drug Administration from 2011 to 2022. The analysis showed that the modalities used for orphan drugs have diversified with increasing emergence of nucleic acid drugs, gene therapies, cell therapies, antibody drugs including next-generation antibodies, and engineered proteins, suggesting that modality diversification enhances the drug development for orphan diseases that are otherwise challenging to treat with conventional drugs. The ratio of orphan drugs targeting only a single disease has increased, likely due to the emergence of gene-specific treatments such as nucleic acid drugs and gene therapies. Moreover, this study found that orphan drugs using different modalities have been competitively developed with the same mechanism of action targeting only a single orphan disease in recent years. In several cases, small-molecule drugs with unique characteristics offer advantages such as dosing convenience and non-genetic patient coverage over nucleic acid drugs, antibody drugs, and gene therapy. These trends suggest the importance of modality technology development and advancement of small molecule optimization technology for future orphan drug development.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"18 ","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42820061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study","authors":"Emerita Quintina de Andrade Moura ,&nbsp;Carolina Dumke de Siqueira ,&nbsp;Ana Carolina Martins ,&nbsp;Bruno Fonseca Nunes ,&nbsp;Ana Carolina Rabello de Moraes ,&nbsp;Fabíola Branco Filippin-Monteiro","doi":"10.1016/j.medidd.2023.100152","DOIUrl":"10.1016/j.medidd.2023.100152","url":null,"abstract":"<div><p>Obesity impacts pharmacokinetic and pharmacodynamic parameters, changing the drug-binding state via plasma proteins, which is critical for drug effectiveness and toxicity. Albumin and α1-acid glycoprotein (AAG) are the two main proteins accountable for drug binding in humans. Previous studies have shown higher values of AAG in individuals with obesity, but the interference of AAG in the pharmacokinetics of drugs remains unclear. We, therefore, aimed to analyze the pharmacotherapeutic profile and interfering factors in patients undergoing bariatric surgery in the pre-operative period and after 12 months. A retrospective cross-sectional study design was conducted and serum AAG was determined, and potential drug-drug interactions were monitored in patients with severe obesity who underwent bariatric surgery. The drug classes most used were antidepressants, cardiovascular agents, and lipid-modifying agents, with a decrease in use after 12 months of surgery. Before surgery, it was found that more than half of the patients had at least one drug interaction in their therapeutic regimen. Of these, most were classified as moderate. After surgery, a decrease in drug interaction was observed. Serum AAG showed a significant reduction after 12 months, which can influence the free fraction of drugs with a high-affinity rate and how they impact therapeutic efficacy.</p></div>","PeriodicalId":33528,"journal":{"name":"Medicine in Drug Discovery","volume":"18 ","pages":"Article 100152"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48546684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}